

Riccardo Soffietti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6800011/riccardo-soffietti-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

209
papers

13,818
citations

58
h-index

116
g-index

235
ext. papers

18,786
ext. citations

5.8
avg. IF

6.35
L-index

#	Paper	IF	Citations
209	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.. <i>EMBO Molecular Medicine</i> , 2022 , e14552	12	2
208	Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program.. <i>Cancers</i> , 2022 , 14,	6.6	2
207	Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
206	Ependymoma: Evaluation and Management Updates.. <i>Current Oncology Reports</i> , 2022 , 1	6.3	0
205	Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
204	Systemic Therapy for Lung Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 110	5.4	1
203	IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. <i>Neuro-Oncology</i> , 2021 ,	1	1
202	Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2021 ,	1	1
201	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. <i>Cancers</i> , 2021 , 13,	6.6	3
200	Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature. <i>Frontiers in Neurology</i> , 2021 , 12, 669493	4.1	2
199	Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. <i>Cancers</i> , 2021 , 13,	6.6	6
198	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021 , 23, 1231-1251	1	708
197	Evaluation of the 2020 European Academy of Neurology virtual congress: transition from a face-to-face to a virtual meeting. <i>European Journal of Neurology</i> , 2021 , 28, 2523-2532	6	5
196	Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. <i>Neuro-Oncology</i> , 2021 , 23, 812-826	1	23
195	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 170-186	19.4	204
194	Evidence-based approaches to chemotherapy for gliomas 2021 , 38-52		
193	Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. <i>European Journal of Neurology</i> , 2021 , 28, 3226-3229	6	7

192	A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology. <i>European Journal of Neurology</i> , 2021 , 28, 3849-3855	6	8
191	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021 , 23, 881-893	1	23
190	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021 , 156, 93-108	7.5	5
189	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021 , 23, 1821-1834	34	32
188	Richter's Syndrome of the Central Nervous System. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-4	1	1
187	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. <i>Current Opinion in Neurology</i> , 2020 , 33, 707-715	7.1	2
186	Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery. <i>Clinical and Experimental Metastasis</i> , 2020 , 37, 499-508	4.7	1
185	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020 , 22, 1568-1579	1	15
184	Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	28
183	Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. <i>Neurological Sciences</i> , 2020 , 41, 1955-1957	3.5	
182	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. <i>Cancer Letters</i> , 2020 , 480, 24-28	9.9	21
181	Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study. <i>Oncotarget</i> , 2020 , 11, 4648-4654	3.3	6
180	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , 2020 , 64, 313-334	1.3	11
179	Epilepsy in CNS Metastases 2020 , 117-125		
178	Prevention Strategies for Brain Metastasis 2020 , 397-406		
177	A call from the European Academy of Neurology on COVID-19. <i>Lancet Neurology</i> , 2020 , 19, 482	24.1	8
176	Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?. <i>Neuro-Oncology</i> , 2020 , 22, 171-172	1	
175	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 1037-1048	3.5	1

174	Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents. <i>Cancers</i> , 2020 , 12,	6.6	2
173	Management of Brain and Leptomeningeal Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
172	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020 , 16, 557-574	15	44
171	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020 , 22, 17-30	1	43
170	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , 2019 , 21, 1610-1611	1	5
169	Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 115-123	4.8	12
168	Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. <i>Neurology</i> , 2019 , 93, 217-219	6.5	2
167	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019 , 21, 571-584	1	67
166	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , 2019 , 126, e270-e280	2.1	8
165	Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. <i>Neuropathology and Applied Neurobiology</i> , 2019 , 45, 655-670	5.2	6
164	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019 , 21, 26-36	1	54
163	Use of Antidepressants and Risk of Incident Stroke: A Systematic Review and Meta-Analysis. <i>Neuroepidemiology</i> , 2019 , 53, 142-151	5.4	20
162	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2007-2007	2.2	12
161	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2045-2045	2.2	2
160	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2056-2056	2.2	1
159	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019 , 78, 248-256	3.1	8
158	Brain Metastases [Clinical Challenges and Recent Advances. <i>European Neurological Review</i> , 2019 , 14, 20	0.5	
157	Tumors of the Central Nervous System: Therapeutic Approaches 2019 , 69-83		

156	Strategies to prevent brain metastasis. <i>Current Opinion in Oncology</i> , 2019 , 31, 493-500	4.2	3
155	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019 , 129, 63-71	5.9	18
154	Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 243-247	13.4	56
153	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 5	51.1	283
152	PET imaging in patients with brain metastasis-report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019 , 21, 585-595	1	72
151	Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series. <i>World Neurosurgery</i> , 2019 , 123, e273-e279	2.1	5
150	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 110-119	21.7	116
149	Supratotal Resection of Glioblastoma: Is Less More?. <i>Surgical Technology International</i> , 2019 , 35, 432-440.	0.8	10
148	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018 , 4, 176-196	12.5	110
147	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , 2018 , 31, 168-179	1.4	0
146	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology, The</i> , 2018 , 19, e33-e42	21.7	27
145	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology, The</i> , 2018 , 19, e20-e32	21.7	63
144	Extent of surgery in low-grade gliomas: an old question in a new context. <i>Neuro-Oncology</i> , 2018 , 20, 6-7	1	5
143	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , 2018 , 20, 445-456	456	100
142	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418759618	6.6	13
141	Breast cancer brain metastasis: molecular mechanisms and directions for treatment. <i>Neuro-Oncology</i> , 2018 , 20, 1439-1449	1	20
140	Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. <i>Journal of Neuro-Oncology</i> , 2018 , 136, 105-114	4.8	20
139	Brain Metastasis as Complication of Systemic Cancers 2018 , 57-79		

138	Neuro-oncology perspective of treatment options in metastatic breast cancer. <i>Future Oncology</i> , 2018 , 14, 1765-1774	3.6	3
137	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018 , 8, 161	5.3	72
136	Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring. <i>BioMed Research International</i> , 2018 , 2018, 3606970	3	47
135	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. <i>Nature Medicine</i> , 2018 , 24, 1024-1035	50.5	156
134	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2047-2047	2.2	3
133	Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor. <i>Journal of Neurosurgical Sciences</i> , 2018 , 62, 229-232	1.3	5
132	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 225-238	1.4	9
131	IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2050-2050	2.2	
130	Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy. <i>Journal of Neurosurgical Sciences</i> , 2018 , 62, 375-378	1.3	0
129	Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Delayed Administration. <i>Anticancer Research</i> , 2018 , 38, 5877-5881	2.3	6
128	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. <i>PLoS ONE</i> , 2018 , 13, e0203570	3.7	9
127	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1272-1275	2.7	2
126	What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?. <i>Current Treatment Options in Neurology</i> , 2018 , 20, 33	4.4	5
125	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1155-1164	8.8	58
124	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017 , 19, 162-174	1	244
123	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology, The</i> , 2017 , 18, e315-e329	21.7	599
122	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 419-427	4.8	38
121	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017 , 19, 625-635	1	87

120 Ependymomas **2017**, 907-916

119	Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?. <i>Neuro-Oncology</i> , 2017 , 19, 1292-1293	1	
118	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 45-56	7.1	12
117	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. <i>Neuro-Oncology</i> , 2017 , 19, 451-453	1	10
116	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1373-1385	21.7	518
115	Evidence-based management of adult patients with diffuse glioma - AuthorsSreply. <i>Lancet Oncology</i> , 2017 , 18, e430-e431	21.7	4
114	Imaging and clinical end points in brain metastases trials. <i>CNS Oncology</i> , 2017 , 6, 243-246	4	4
113	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017 , 82, 193-202	7.5	21
112	Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. <i>Annals of Oncology</i> , 2017 , 28, 2588-2594	10.3	22
111	Controversies in management of low-grade gliomas in light of new data from clinical trials. <i>Neuro-Oncology</i> , 2017 , 19, 143-144	1	8
110	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 45-56	7.1	12
109	Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. <i>Oncotarget</i> , 2017 , 8, 67696-67708	3.3	12
108	Natural History and Spontaneous Prognostic Factors 2017 , 307-322		
107	A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2026-2026	2.2	
106	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , 2017 , 19, 484-492	1	101
105	Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. <i>European Radiology</i> , 2016 , 26, 1263-73	8	19
104	Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. <i>Neuro-Oncology</i> , 2016 , 18, 261-8	1	25
103	Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. <i>Neurological Sciences</i> , 2016 , 37, 2019-2023	3.5	1

102 Spinal epidural metastases **2016**, 596-598

101	Treatment of brain metastasis: current status and future directions. <i>Current Opinion in Oncology</i> , 2016 , 28, 502-510	4.2	9
100	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 744-51	1	46
99	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2468-77	2.2	113
98	Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?. <i>Neuro-Oncology</i> , 2016 , 18, 12-5	1	6
97	Rare glial tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 399-415	3	10
96	Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response. <i>Journal of Neuro-Oncology</i> , 2016 , 127, 201-3	4.8	3
95	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016 , 18, 401-7	1	41
94	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. <i>Oncotarget</i> , 2016 , 7, 21190-8	3.3	15
93	Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2047-2047	2.2	27
92	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016 , 18, 1043-65	1	158
91	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1199-208	1	398
90	EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology, The</i> , 2016 , 17, e383-217	2.1	414
89	Molecularly based management of gliomas in clinical practice. <i>Neurological Sciences</i> , 2015 , 36, 1551-7	3.5	4
88	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 1994-1999	10.3	93
87	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology, The</i> , 2015 , 16, e322-32	21.7	247
86	What is New in the Management of Epilepsy in Gliomas?. <i>Current Treatment Options in Neurology</i> , 2015 , 17, 351	4.4	27
85	Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. <i>BMC Cancer</i> , 2015 , 15, 486	4.8	18

84	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015 , 17, 440-7	1	83
83	Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage. <i>Tumori</i> , 2015 , 101, e167-70	1.7	5
82	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology, The</i> , 2015 , 16, e270-8	21.7	472
81	A comprehensive characterization of mitochondrial DNA mutations in glioblastoma multiforme. <i>International Journal of Biochemistry and Cell Biology</i> , 2015 , 63, 46-54	5.6	18
80	GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2054-2054	2.2	
79	Is there a Role for Bevacizumab in Non-Glial Tumors?. <i>Current Drug Targets</i> , 2015 , 16, 684-8	3	
78	MGMT promoter methylation in plasma of glioma patients receiving temozolomide. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 347-57	4.8	38
77	Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2014 , 116, 533-41	4.8	58
76	The legend of cytomegalovirus and glioblastoma lives on. <i>Neuro-Oncology</i> , 2014 , 16, 166	1	8
75	Neurologic complications of chemotherapy and other newer and experimental approaches. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014 , 121, 1199-218	3	38
74	Pharmacologic therapies for malignant glioma: a guide for clinicians. <i>CNS Drugs</i> , 2014 , 28, 1127-37	6.7	9
73	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. <i>Neuro-Oncology</i> , 2014 , 16, 173-8	1	22
72	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology, The</i> , 2014 , 15, e395-403	21.7	498
71	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , 2014 , 16, 1176-85	1	116
70	PRE-OPERATIVE CHEMOTHERAPY AS A NEW STRATEGY OF TREATMENT FOR LOW GRADE GLIOMAS IN ELOQUENT AREAS. <i>Neuro-Oncology</i> , 2014 , 16, iii45-iii45	1	78
69	Still a long way to go to achieve multidisciplinary for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9-15, 2014). <i>Annals of Oncology</i> , 2014 , 25, 1863-1865	10.3	5
68	Antiangiogenic therapy of brain tumors: the role of bevacizumab. <i>Neurological Sciences</i> , 2014 , 35, 507-14	5.5	9
67	Leptomeningeal metastases: A rano proposal for response criteria.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13019-e13019	2.2	

66	MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2016-2016	2.2	
65	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , 14, e396-406	21.7	92
64	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , 14, e407-16	21.7	97
63	A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. <i>Journal of Clinical Oncology</i> , 2013 , 31, 65-72	2.2	443
62	Ependymoma: current treatment options and a look to the future. <i>CNS Oncology</i> , 2013 , 2, 223-5	4	1
61	Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. <i>Neuro-Oncology</i> , 2013 , 15, 1739-49	1	60
60	Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression. <i>Journal of Clinical Oncology</i> , 2013 , 31, e394-7	2.2	1
59	Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. <i>Brain Pathology</i> , 2013 , 23, 584-94	6	45
58	Reply to M.C. Chamberlain and C. Gemici. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2636-7	2.2	1
57	Natural History and Spontaneous Prognostic Factors 2013 , 265-275		2
56	Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 353-66	4.8	82
55	Epidemiology of glial and non-glial brain tumours in Europe. <i>European Journal of Cancer</i> , 2012 , 48, 1532-45	4.5	212
54	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 20-26	1.6	
53	Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. <i>European Journal of Cancer</i> , 2012 , 48, 3439-47	7.5	33
52	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012 , 123, 727-38	14.3	131
51	Brain metastases. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 747-55		17
50	Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv55-64	1	162
49	Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 551-67	3	1

48	Targeted therapy in brain metastasis. <i>Current Opinion in Oncology</i> , 2012 , 24, 679-86	4.2	61
47	Anti-angiogenic approaches to malignant gliomas. <i>Current Cancer Drug Targets</i> , 2012 , 12, 279-88	2.8	12
46	Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2037-2037	2.2	3
45	Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 134-41	2.2	1369
44	Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. <i>European Journal of Neurology</i> , 2011 , 18, 19-e3	6	332
43	Ependymomas 2011 , 249-262		
42	Epilepsy and brain tumors. <i>Current Opinion in Oncology</i> , 2010 , 22, 611-20	4.2	118
41	Ependymomas in adults. <i>Current Neurology and Neuroscience Reports</i> , 2010 , 10, 240-7	6.6	106
40	Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. <i>Journal of Neuro-Oncology</i> , 2010 , 97, 439-44	4.8	6
39	Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. <i>European Journal of Neurology</i> , 2010 , 17, 1124-1133	6	374
38	The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. <i>Seminars in Oncology</i> , 2009 , 36, 555-68	5.5	8
37	Skin metastases of glioblastoma in the absence of intracranial progression are associated with a shift towards a mesenchymal immunophenotype: report of two cases. <i>Acta Neuropathologica</i> , 2009 , 118, 313-6	14.3	10
36	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009 , 374, 1512-20	4.0	478
35	Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009 , 68, 425-31	3.1	16
34	The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in Western patients with intravascular large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008 , 143, 253-7	4.5	70
33	Neuro-oncology: new insights and advances in treatment. <i>Lancet Neurology, The</i> , 2008 , 7, 14-6	24.1	3
32	Brain metastases: current management and new developments. <i>Current Opinion in Oncology</i> , 2008 , 20, 676-84	4.2	116
31	Ependymomas of the adult: molecular biology and treatment. <i>Current Opinion in Neurology</i> , 2008 , 21, 754-61	7.1	68

30	Natural history and management of brainstem gliomas in adults. A retrospective Italian study. <i>Journal of Neurology</i> , 2008 , 255, 171-7	5.5	69
29	New developments in the treatment of malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 1313-26	4.3	17
28	New chemotherapy options for the treatment of malignant gliomas. <i>Anti-Cancer Drugs</i> , 2007 , 18, 621-32.	4	15
27	Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors. <i>European Journal of Endocrinology</i> , 2006 , 155, 559-66	6.5	37
26	EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 674-81	6	157
25	Radiotherapy and chemotherapy of brain metastases. <i>Journal of Neuro-Oncology</i> , 2005 , 75, 31-42	4.8	28
24	Chemotherapy of anaplastic oligodendroglial tumours. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 295-306	4	12
23	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. <i>Cancer</i> , 2004 , 100, 807-13	6.4	33
22	Management of brain metastases. <i>Journal of Neurology</i> , 2002 , 249, 1357-69	5.5	277
21	The position of the neurologist in neuro-oncology. <i>European Journal of Neurology</i> , 2002 , 9, 201-5	6	3
20	Brain metastases from unknown primary tumour: a prospective study. <i>Journal of Neurology</i> , 2001 , 248, 394-8	5.5	55
19	Primitive cerebral melanoma: case report and review of the literature. <i>World Neurosurgery</i> , 2001 , 55, 163-8; discussion 168		61
18	PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. <i>Neurosurgery</i> , 1998 , 43, 1066-73	3.2	142
17	Cranial and Spinal Meningeal Carcinomatosis MR Findings. <i>The Neuroradiology Journal</i> , 1997 , 10, 585-595		1
16	MRI diagnosis of intramedullary metastases from extra-CNS tumors. <i>European Radiology</i> , 1997 , 7, 732-6	8	32
15	Prognostic Factors in Adult Medulloblastoma. A Clinico-Pathologic Study. <i>Tumori</i> , 1995 , 81, 338-346	1.7	22
14	Proliferating Cell Nuclear Antigen (PCNA) in Low-Grade Astrocytomas: Its Prognostic Significance. <i>Tumori</i> , 1994 , 80, 295-300	1.7	7
13	Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas. <i>Neuroradiology</i> , 1992 , 34, 73-6	3.2	8

12	Ependymoma: Internal Correlations among Pathological Signs: The Anaplastic Variant. <i>Neurosurgery</i> , 1991 , 29, 206-210	3.2	63
11	Histologic prognostic factors in ependymoma. <i>Childs Nervous System</i> , 1991 , 7, 177-82	1.7	122
10	Vascular response to irradiation in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 1990 , 8, 73-84	4.8	6
9	Prognostic factors in well-differentiated cerebral astrocytomas in the adult. <i>Neurosurgery</i> , 1989 , 24, 686-92	3.2	191
8	Prognostic value of histologic factors in adult cerebral astrocytoma. <i>Cancer</i> , 1988 , 61, 1386-93	6.4	45
7	Primary Lymphomas of the Brain: A Clinico-Pathologic Review of 37 Cases. <i>Tumori</i> , 1987 , 73, 585-592	1.7	15
6	Delayed adverse effects after irradiation of gliomas: clinicopathological analysis. <i>Journal of Neuro-Oncology</i> , 1985 , 3, 187-92	4.8	22
5	Effects of radiotherapy on the astrocytomatous areas of malignant gliomas. <i>Journal of Neuro-Oncology</i> , 1984 , 2, 167-75	4.8	5
4	Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy. <i>Acta Neuropathologica</i> , 1982 , 58, 291-9	14.3	31
3	A Pathologic Study of Malignant Gliomas Operated after Radio- and Chemotherapy. <i>Tumori</i> , 1981 , 67, 13-17	1.7	
2	Radio- and chemotherapy of malignant gliomas. Pathological changes in the normal nervous tissue. <i>Acta Neurochirurgica</i> , 1981 , 58, 37-58	3	20
1	On the Nature of the So-Called Monstrocellular Sarcoma of the Brain. <i>Neurosurgery</i> , 1980 , 6, 391-397	3.2	3